Übersetzung für "Dermatomyositis" in Deutsch

Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)

More than 90% of anti-Mi-2 positive patients have dermatomyositis.

The exact cause of dermatomyositis is not known.

Children, adolescents and adults can all develop dermatomyositis.

Dermatomyositis is an inherited inflammatory disease of the skin, muscles, and blood vessels.

In 20-30% of cases dermatomyositis observed in patients with various tumors.

There are some differences between adult and juvenile dermatomyositis.

Polymositis and dermatomyositis are both generalized disorders which involve the inflammation of the dog’s muscles.

An apparent hypersensitivity syndrome has been reported rarely which has included some of the following features: angioedema, lupus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, ESR increased, arthritis and arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea and malaise.

These autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren's syndrome and dermatomyositis/ polymyositis.

These autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren's syndrome and dermatomyositis/polymyositis.

The cutaneous manifestations of dermatomyositis may or may not improve with therapy in parallel with the improvement of the myositis.

The Center for Pediatric and Adolescent Rheumatology treats children and adolescents with rheumatic diseases including juvenile idiopathic arthritis, but also systemic lupus erythematosus, juvenile dermatomyositis, scleroderma and other connective tissue disorders.

Secondary autoantibodies of this type against proteins from the lipocortin family have been described in rheumatic disorders (systemic lupus erythematosus, rheumatoid arthritis and dermatomyositis) (Hirata, F. et al., Proc.

Collagen vascular disorders include progressive systemic sclerosis, polymyositis, sclerorma, dermatomyositis, eosinophilic fascitis, morphea, or those associated with the occurrence of Raynaud's syndrome.

Further, it is preferable if the autoimmune disease is selected from the group consisting of: type I diabetes mellitus, rheumatoid arthritis, multiple sclerosis, chronic gastritis, Crohn's disease, Basedow disease, Bechterew disease, psoriasis, myasthenia gravis, autoimmune hepatitis, APECED, Chrug-Strauss syndrome, ulcerative colitis, glomerulonephritis, Guillain-Barré syndrome, Hashimoto thyroiditis, lichen sclerosus, systemic lupus erythematodes, PANDAS, rheumatic fever, sarcoidosis, Sjörgren syndrome, Stiff-Man syndrome, scleroderma, Wegener's granulomatosis, vitiligo, autoimmune enteropathy, Goodpasture syndrome, dermatomyositis, polymyositis, autoimmune allergy, asthma and autoimmune reaction after organ transplantations.

Prednisolone is used for the treatment of a wide range of inflammatory and auto-immune conditions such as asthma, uveitis, rheumatoid arthritis, ulcerative colitis and Crohn's disease, Bell's palsy, multiple sclerosis, cluster headaches, systemic lupus erythematosus, and Dermatomyositis.

Symptoms of dermatomyositis are usually seen in affected dogs before they are six months of age.

A Canadian team (Garneau et al) presents data on the treatment of patients with myasthenia gravis, dermatomyositis, neuromyelitis optica, NMDA, encephalitis, vasculitis, and CIDP using the monoclonal antibody rituximab, which is established in oncology and rheumatology.

Juvenile dermatomyositis (JDM) is a rare disease that affects muscles and skin.

While extremely successful in Guillain-Barre, Kawasaki and Dermatomyositis, IVIG therapy has also shown a great deal of promise in PANDAS and PITAND syndromes, post-infectious Encephalitis and ADEM (into this group belongs a vaccine induced brain damage), and Opsoclonus-Myoclonus (without Neuroblastoma).

Collagen vascular disorders include progressive systemic sclerosis, polymyositis, sclerodermatitis, dermatomyositis, eosinophilic fasciitis, morphea, or those associated with the occurrence of Raynaud's syndrome.

The compounds of the invention can further be used for the prophylaxis and/or treatment of inflammatory disorders caused for example by viruses, spirochetes, fungi, bacteria or mycobacteria, and of inflammatory disorders of unknown etiology, such as polyarthritis, lupus erythematosus, peri- or polyarteritis, dermatomyositis, scleroderma and sarcoidosis.